Form 4: Cynthia Collins Reports Acquisition of MaxCyte Stock and Options

Director Cynthia Collins reports acquisition of MaxCyte stock and options, including restricted stock units and stock options, in a recent Form 4 filing.

Summary

• Cynthia Collins, a director of MaxCyte, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On October 14, 2024, Collins acquired 51,679 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs will vest on October 14, 2025, contingent upon continued service to the Issuer.
• Collins also acquired options to purchase 97,698 shares of common stock at an exercise price of $3.87 on the same date.
• One-third of these options will vest on October 14, 2025, with the remainder vesting in 24 equal monthly installments, also subject to continued service.
• Following these transactions, Collins beneficially owns 51,679 shares of common stock and options for 97,698 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option acquisitions by a director. The vesting schedule indicates a long-term commitment.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates the director's investment in the company.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder sentiment.

Key Dates